神经保护市场 - 副产品（抗氧化剂、细胞凋亡抑制剂、抗发炎药物、谷氨酸拮抗剂、金属离子螯合剂、抗忧郁药物）、给药途径、应用、配销通路- 全球预测 2024 - 2032

由于该领域的研究和开发不断增加，2024 年至 2032 年全球神经保护市场的复合年增长率将达到 7.1%。神经保护涉及旨在保护大脑和神经系统中神经元的结构和功能的策略。随着我们对神经系统疾病和损伤的了解不断加深，对有效神经保护治疗的需求也不断增加。

例如，2023 年 10 月，两项关于针对急性缺血性中风患者的潜在神经保护剂 nerinetide (NoNO Inc) 的最新研究揭示了相互矛盾但有趣的发现。领导 ESCAPE-NEXT 试验的加拿大卡加利大学神经病学教授 Michael Hill 博士承认该试验的结果令人失望。然而，他表示 FRONTIER 结果非常有希望，并表明儘早使用该药物的重要性。

研究人员正在探索各种方法，包括药物介入、基因治疗、干细胞治疗和神经保护剂。随着神经科学的进步，人们越来越乐观地开发新疗法来预防或减缓阿兹海默症、帕金森氏症和多发性硬化症等神经退化性疾病的进展。因此，对神经保护疗法的需求不断增长，推动了神经保护市场的成长。

整个神经保护产业根据产品、给药途径、应用、配销通路和地区进行分类。

细胞凋亡抑制剂领域将在 2024 年至 2032 年经历显着发展。细胞凋亡抑制剂旨在阻断此过程，保留神经元功能和结构。这些抑制剂有望治疗中风、阿兹海默症和帕金森氏症等疾病。随着研究的进展，更有效的细胞凋亡抑制剂正在开发中，推动了神经保护市场的需求。细胞凋亡抑制剂可能减缓或阻止神经退化的能力使它们成为寻求新型神经保护疗法的焦点。

从 2024 年到 2032 年，静脉注射领域的神经保护市场份额将实现显着的复合年增长率。这种途径对于中风、脑部外伤和神经退化性疾病等需要立即采取行动的急性疾病尤其重要。此外，静脉注射可以实现精确剂量和连续输注，从而优化治疗效果。随着研究人员开发出适合静脉注射的新型神经保护剂和製剂，对此类治疗的需求持续增长，从而塑造了神经保护市场格局。

亚太地区神经保护市场从2024年到2032年将呈现出令人称讚的复合年增长率。亚太地区国家正在投资医疗基础设施和研究，促进神经保护疗法的创新和发展。此外，可支配收入的增加和对神经健康的认识正在推动对这些治疗的需求。各国政府正在实施政策来满足医疗保健需求，进一步推动市场成长。因此，亚太地区正在成为神经保护研究和开发的焦点，推动对神经保护疗法的需求。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 神经系统疾病盛行率增加
    • 药物输送系统的技术进步
    • 人口老化与人口结构变化
    • 增加研发投入
  • 产业陷阱与挑战
    • 严格的监管场景
• 成长潜力分析
• 技术景观
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 竞争定位矩阵
• 战略展望矩阵

第 5 章：市场估计与预测：按产品分类，2018 年 - 2032 年

• 主要趋势
• 抗氧化剂
• 细胞凋亡抑制剂
• 抗发炎剂
• 麸胺酸拮抗剂
• 金属离子螯合剂
• 抗忧郁药
• 兴奋剂
• 神经营养因子 (NTF)
• 其他产品

第 6 章：市场估计与预测：按管理途径，2018 年 - 2032 年

• 主要趋势
• 口服
• 静脉
• 其他给药途径

第 7 章：市场估计与预测：按应用划分，2018 年 - 2032 年

• 主要趋势
• 神经退化性疾病
• 中风和缺血性损伤
• 创伤性脑损伤 (TBI)
• 忧郁症和躁郁症
• 脊髓损伤
• 其他应用

第 8 章：市场估计与预测：按配销通路，2018 年 - 2032 年

• 主要趋势
• 医院药房
• 零售药局
• 药局
• 网路药局

第 9 章：市场估计与预测：按地区划分，2018 年 - 2032 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋
  • 中东和非洲其他地区

第 10 章：公司简介

• AbbVie Inc.
• Biogen Inc.
• Dr. Reddy's Laboratories Ltd.
• Eli Lilly and Company
• GSK plc
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi
• Teva Pharmaceutical Industries Limited

Global Neuroprotection Market will witness 7.1% CAGR between 2024 and 2032 due to increasing research and development in the field. Neuroprotection involves strategies aimed at preserving the structure and function of neurons in the brain and nervous system. As our understanding of neurological diseases and injuries improves, so does the need for effective neuroprotective treatments.

For instance, in October 2023, two recent studies on the potential neuroprotective agent nerinetide (NoNO Inc) for acute ischemic stroke patients revealed conflicting yet intriguing findings. Michael Hill, MD, a neurology professor at the University of Calgary, Canada, who led the ESCAPE-NEXT trial, admitted that the trial's results were disappointing. However, he expressed that the FRONTIER results were highly promising and indicated the importance of administering this agent as early as feasible.

Researchers are exploring various approaches, including pharmacological interventions, gene therapy, stem cell therapy, and neuroprotective agents. With advancements in neuroscience, there is growing optimism for the development of novel treatments to prevent or slow down the progression of neurodegenerative diseases like Alzheimer's, Parkinson's, and multiple sclerosis. Consequently, there is a rising demand for neuroprotective therapies, driving growth in the neuroprotection market.

The overall Neuroprotection Industry is classified based on the product, route of administration, application, distribution channel, and region.

The apoptosis inhibitors segment will undergo notable development from 2024 to 2032. Apoptosis, or programmed cell death, plays a significant role in neurodegenerative diseases and injuries by causing the death of neurons. Apoptosis inhibitors are designed to block this process, preserving neuronal function and structure. These inhibitors hold promise in treating conditions like stroke, Alzheimer's, and Parkinson's disease. As research advances, more effective apoptosis inhibitors are being developed, driving demand in the neuroprotection market. The ability of apoptosis inhibitors to potentially slow or halt neurodegeneration makes them a focal point in the quest for novel neuroprotective therapies.

The neuroprotection market share from the intravenous segment will register a noteworthy CAGR from 2024 to 2032. Intravenous delivery offers direct and rapid access to the bloodstream, ensuring efficient distribution of neuroprotective agents to the brain and spinal cord. This route is particularly crucial in acute conditions like stroke, traumatic brain injury, and neurodegenerative diseases where immediate action is required. Additionally, intravenous administration allows for precise dosing and continuous infusion, optimizing therapeutic outcomes. As researchers develop new neuroprotective agents and formulations suitable for intravenous delivery, the demand for such treatments continues to grow, shaping the neuroprotection market landscape.

Asia Pacific neuroprotection market will showcase a commendable CAGR from 2024 to 2032. With a rapidly aging population and increasing incidence of neurological disorders, there's a pressing need for effective treatments. Countries in Asia-Pacific are investing in healthcare infrastructure and research, fostering innovation and development of neuroprotective therapies. Moreover, rising disposable incomes and awareness about neurological health are propelling demand for these treatments. Governments are implementing policies to address healthcare needs, further boosting market growth. As a result, the Asia-Pacific region is becoming a focal point for neuroprotection research and development, driving demand for neuroprotective therapies.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of neurological disorders
    • 3.2.1.2 Technological advancements in drug delivery systems
    • 3.2.1.3 Aging population and demographic shifts
    • 3.2.1.4 Increasing research and development investments
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Stringent regulatory scenario
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
  • 3.6.1 Supplier power
  • 3.6.2 Buyer power
  • 3.6.3 Threat of new entrants
  • 3.6.4 Threat of substitutes
  • 3.6.5 Industry rivalry
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Antioxidants
• 5.3 Apoptosis inhibitors
• 5.4 Anti-inflammatory agents
• 5.5 Glutamate antagonists
• 5.6 Metal ion chelators
• 5.7 Antidepressants
• 5.8 Stimulants
• 5.9 Neurotrophic factors (NTFs)
• 5.10 Other products

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Oral
• 6.3 Intravenous
• 6.4 Other routes of administration

Chapter 7 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Neurodegenerative diseases
• 7.3 Stroke and ischemic injury
• 7.4 Traumatic brain injury (TBI)
• 7.5 Depression and bipolar disorders
• 7.6 Spinal cord injury
• 7.7 Other applications

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Drug stores
• 8.5 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 AbbVie Inc.
• 10.2 Biogen Inc.
• 10.3 Dr. Reddy's Laboratories Ltd.
• 10.4 Eli Lilly and Company
• 10.5 GSK plc
• 10.6 Merck & Co., Inc.
• 10.7 Novartis AG
• 10.8 Pfizer Inc.
• 10.9 Sanofi
• 10.10 Teva Pharmaceutical Industries Limited